Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on August 27, 2018, reporting corporate governance changes effective August 28, 2018. The Company is a Delaware corporation headquartered in Cambridge, Massachusetts, and is classified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and director compensation.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to nine directors.
- New Director Election: Cynthia Smith was elected as a Class II director to fill the vacancy, with a term expiring at the 2019 annual meeting of stockholders.
- Committee Assignments: The Board has not yet determined Ms. Smith's committee assignments.
Compensation and Governance Details
Ms. Smith's compensation is governed by the Company's Amended and Restated Non-Employee Director Compensation Program:
- Cash Retainer: Eligible for an annual cash retainer of $40,000.
- Equity Grant: Granted an option to purchase 25,000 shares of common stock on August 28, 2018.
- Indemnification: Entitled to the same right to indemnification as other non-employee directors.
The filing states there are no arrangements or understandings between Ms. Smith and other persons regarding her selection.
Key Facts for Investor Verification
- Verify the total number of outstanding shares and the dilution impact of the 25,000 share option grant.
- Confirm the specific committee assignments for Ms. Smith once determined by the Board.
- Review the Company's latest 10-Q or 10-K for current financial health, as this 8-K contains no financial performance data.